PYPD
PolyPid Ltd.
stockNASDAQ
polypid®, a specialty pharmaceutical company, develops and manufactures products based on its plex™ technology. so far, 70 patients have been treated in clinical trials with polypid's anti-infection products demonstrating safety and efficacy. polypid is in the process of submitting its lead product for phase-iii trial in the us and eu. plex™ is able to optimize drugs' therapeutic performance and clinical outcomes. plex™-based protected drug reservoir is implanted directly into the body's target area thus enabling prolonged delivery of drugs, over periods ranging from days to several months. polypid's pipeline focuses on 3 products: d-plex™ - intended for prevention and treatment of surgical infections caused by bacteria. its effectiveness is currently being tested in patients undergoing open-heart surgery, with a view to preventing infections that may occur following surgery. the product is currently undergoing clinical studies at several medical centers. bonypid®-1000 - designed to e
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 4.88 | 2026-10-13 | +5.53% | 3.359 |
| 1M | 5.17 | 2026-09-21 | -0.39% | 1.180 |
| 6M | 4.69 | 2026-04-20 | +9.81% | 0.403 |
| 1Y | 3.20 | 2025-10-20 | +60.94% | 0.849 |
| 2Y | 3.30 | 2024-10-21 | +56.06% | — |
| 5Y | 226.50 | 2021-10-20 | -97.73% | 0.336 |
PolyPid Ltd. (NASDAQ:PYPD) stock price today is $5.15, and today's volume is 95,702. PYPD is up 5.533% today. The 30 day average volume is 95,555. PYPD market cap is $104.61M with 20.31M shares outstanding.